Abstract

Effectively targeting deregulated KRAS signaling remains an unmet clinical need, as current approaches commonly lead to the development of chemoresistance in clinical settings. ADAM9-mediated lysosomal KRAS degradation is now shown to counteract PDAC chemoresistance independently of mutational status.

Original languageEnglish
Pages (from-to)375-377
Number of pages3
JournalNature Cancer
Volume5
Issue number3
DOIs
StatePublished - Mar 2024

Fingerprint

Dive into the research topics of 'KRAS degradation averts PDAC chemoresistance'. Together they form a unique fingerprint.

Cite this